Tempus AI Has Set Itself Up for Another Consensus-Beating Quarter

Tempus AI (TEM) reports second-quarter 2026 earnings after market close on July 30, with analysts expecting a loss of $0.41 per share on revenue of $381.6 million. The central question is whether the healthcare technology company can demonstrate a path toward profitability following its recent $1.5 billion acquisition of Personalis, while navigating concerns about stock dilution and a challenging market environment that has pushed shares 31% below their 200-day moving average.

Part 1: Earnings Preview

Company Overview: Tempus AI operates as a healthcare technology company offering a closed-loop platform that integrates clinical diagnostics, AI-powered analytics, and a multimodal data repository to advance precision medicine. The company provides NGS diagnostics, genomic testing, and software applications for both healthcare providers and life sciences research.

Earnings Expectations: Tempus reports Q2 2026 results on Thursday, July 30, after market close. Analysts expect a loss of $0.41 per share on revenue of $381.58 million, representing 21.3% year-over-year revenue growth. The company most recently reported a loss of $0.37 per share for Q1 2026. Compared to the same quarter last year (Q2 2025), when Tempus posted a loss of $0.36 per share, the consensus estimate implies a 13.89% deterioration in losses year-over-year.

Key Narrative Themes:

1. Personalis Acquisition Integration: The recent $1.5 billion acquisition of Personalis raises critical questions about near-term profitability and potential stock dilution. Investors will scrutinize management's integration timeline and whether the deal accelerates Tempus's path to positive earnings or extends the loss trajectory.

2. Path to Profitability: After achieving positive Adjusted EBITDA for the first time in recent quarters, with management guiding to $65 million of 2026 EBITDA, investors are watching whether operational leverage can offset the widening GAAP losses reflected in consensus estimates.

3. Revenue Growth Deceleration: Revenue growth has slowed from 83.4% to approximately 69% in recent quarters, and the 21.3% expected growth for Q2 represents further deceleration. The sustainability of Tempus's growth trajectory amid this slowdown is a central concern.

Analyst Commentary: Zacks Equity Research notes that Tempus's Most Accurate Estimate of a $0.32 loss is significantly better than the consensus $0.41 loss, producing an Earnings ESP of +21.74%, which suggests analysts have recently become more bullish on near-term prospects. However, the stock carries a Zacks Rank of #3 (Hold), indicating mixed conviction despite the positive earnings surprise potential.

Part 2: Historical Earnings Performance

Tempus has demonstrated a strong pattern of beating earnings estimates, exceeding consensus in three of the last four quarters. The company delivered impressive surprises of +23.40% in Q2 2025, +16.22% in Q3 2025, and +21.28% in Q1 2026, with only Q4 2025 posting a modest -7.41% miss.

The magnitude of beats has been substantial, with the company consistently reporting losses that were $0.06 to $0.11 per share better than expected. This pattern suggests management has been conservative in guiding expectations or that the business is executing better than analysts anticipated. The Q1 2026 beat of +21.28% is particularly notable, as it came despite a more challenging estimate of a $0.47 loss versus the $0.37 actual loss.

The trend shows improving operational performance, with reported losses narrowing from $0.36 in Q2 2025 to $0.29 in Q4 2025, before widening slightly to $0.37 in Q1 2026. Given the consistent beat pattern and the positive Earnings ESP of +21.74% for the upcoming quarter, Tempus appears well-positioned to exceed the $0.41 consensus loss estimate once again.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Tempus reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual earnings report.

Tempus exhibits volatile post-earnings price action with an average absolute Day 0 move of 4.02% and Day +1 move of 6.67%. The Day +1 reaction tends to be more pronounced, with an average range of 11.45% compared to Day 0's 8.38% range, suggesting the market takes time to fully digest results.

The direction of moves has been mixed but skewed negative on Day +1, with notable examples including a -15.05% plunge in February 2025 and a -10.10% drop in November 2024, despite positive Day 0 reactions. However, the stock has also delivered explosive upside, including a +12.59% Day +1 surge in May 2025. The most recent earnings (May 2026) saw a modest -3.12% Day 0 decline followed by a -1.05% Day +1 move, suggesting more muted volatility than the historical average.

Part 2.2: Options Market Expected Move

The options market is pricing a 7.57% expected move for this earnings release, which is below the historical average Day +1 move of 6.67% but well below the 11.45% average Day +1 range. This suggests options traders are anticipating somewhat subdued volatility compared to Tempus's typical post-earnings behavior, though the stock's history of double-digit swings indicates potential for moves beyond the expected range.

Part 3: What Analysts Are Saying

Current Analyst Consensus: Analysts maintain a mixed-to-cautious stance on Tempus AI, with an average recommendation of 3.83 (between Hold and Buy) and a mean price target of $66.75, implying 61% upside from the current price of $41.55. The target range is exceptionally wide, spanning from $35.00 to $100.00, reflecting significant disagreement about the company's valuation.

Rating Breakdown: The analyst community is divided, with 7 Strong Buys and 2 Moderate Buys offset by 8 Hold ratings and 1 Moderate Sell. This distribution suggests cautious optimism, with half the coverage viewing the stock as a buy opportunity while the other half recommends waiting for more clarity.

Sentiment Shift: Analyst sentiment has deteriorated over the past month, with the average recommendation declining from 3.94 to 3.83 and Strong Buy ratings dropping from 8 to 7. Hold ratings increased from 7 to 8, indicating some analysts have downgraded their stance, likely reflecting concerns about the Personalis acquisition's impact and the stock's recent underperformance.

Valuation Implications: The consensus price target of $66.75 represents substantial upside potential, but the current price of $41.55 sits 38% below that target and closer to the low-end estimate of $35.00. This disconnect suggests either significant skepticism about near-term execution or an opportunity for investors who believe in the long-term precision medicine thesis.

Part 4: Technical Picture

The Barchart Technical Opinion shows a 56% Sell signal, unchanged from last week but representing a sharp deterioration from the 8% Sell signal one month ago. This rapid shift reflects the stock's recent weakness, with TEM now trading below all major moving averages.

Timeframe Analysis:

• Short-term (Hold): Neutral signal suggests near-term momentum has stalled after the recent decline
• Medium-term (50% Sell): Moderate sell signal indicates deteriorating intermediate-term trend structure
• Long-term (100% Sell): Strong sell signal reflects significant weakness in the longer-term trend, with the stock well below its 200-day moving average

Trend Characteristics: The combination of Good strength with Average direction suggests the stock is experiencing a well-defined downtrend with consistent momentum, rather than erratic or choppy price action.

Moving Average Analysis: TEM is trading below all key moving averages, including the 5-day ($43.21), 10-day ($46.65), 20-day ($52.90), 50-day ($51.05), 100-day ($50.41), and 200-day ($59.91). The stock is particularly extended below its 200-day average, sitting 31% below that long-term trend line at $41.55.

The technical setup heading into earnings is decidedly bearish, with the stock in a clear downtrend and no nearby support from moving averages. The 52-week low of $41.73 represents immediate support just $0.18 below current levels, making this a critical technical juncture. A positive earnings surprise could trigger a sharp reversal given the oversold positioning, but failure to beat estimates would likely test new lows. The uniformly negative moving average alignment suggests any rally will face resistance at multiple levels, with the 5-day average at $43.21 representing the first hurdle.